Molecular mechanisms underlying the genetic association between PPP1R3B and hepatic steatosis

PPP1R3B与肝脂肪变性遗传关联的分子机制

基本信息

  • 批准号:
    10224175
  • 负责人:
  • 金额:
    $ 54.11万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-08-01 至 2023-07-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY Non-alcoholic fatty liver disease (NAFLD) is a major public health issue that affects millions of Americans, and that is increasing in prevalence with the global rise in obesity. Cutting edge human genetic approaches have identified natural human genetic variants associated with liver fat. Of these, associations with two genes: PNPLA3, and PPP1R3B, have been replicated in multiple studies. We have developed unique new mouse models to help us understand how increased PPP1R3B protects against fatty liver. PPP1R3B encodes a protein known to regulate liver glycogen, but which has only been connected to liver fat by genetic association: in other words, the role of PPP1R3B in liver fat metabolism is unknown. Interestingly, PPP1R3B is also genetically associated with multiple traits relevant to human metabolic health, including fasting insulin and glucose, plasma lactate, alkaline phosphatase, and plasma cholesterol (total, LDL and HDL cholesterol). All of these association signals map quite far from the end of the PPP1R3B gene, to a long non-coding RNA (lncRNA) of unknown function, LOC157273. Despite the considerable physical distance, genetic variants were found to correlate with increased liver PPP1R3B RNA. The minor allele (occurring in ~9% of Europeans) is associated with increased hepatic PPP1R3B mRNA expression and reduced liver and plasma lipids. Our preliminary data in mice strongly suggest that PPP1R3B is the causal gene: liver-specific PPP1R3B knockout mice (Ppp1r3bΔhep) have increased hepatic and plasma lipids, whereas increasing Ppp1r3b levels in liver reduces hepatic and plasma lipids. We propose to elucidate the mechanisms by which hepatic PPP1R3B influences hepatic fat and plasma cholesterol, and to determine how the natural variants increase expression of the PPP1R3B gene. !
项目总结 非酒精性脂肪性肝病(NAFLD)是一个影响数百万美国人的重大公共卫生问题, 随着全球肥胖率的上升,这一问题的患病率正在上升。尖端的人类遗传方法已经 确定了与肝脏脂肪相关的自然人类遗传变异。其中,与两个基因有关: PNPLA3和PPP1R3B已在多项研究中复制。我们开发了独特的新型鼠标 帮助我们了解增加的PPP1R3B如何预防脂肪肝的模型。PPP1R3B编码一个 已知的调节肝糖原的蛋白质,但仅通过基因联系与肝脏脂肪有关: 换句话说,PPP1R3B在肝脏脂肪代谢中的作用尚不清楚。 有趣的是,PPP1R3B基因还与多种与人类代谢健康相关的性状有关, 包括空腹胰岛素和血糖、血浆乳酸、碱性磷酸酶和血浆胆固醇(总低密度脂蛋白 和高密度脂蛋白胆固醇)。所有这些关联信号都从PPP1R3B基因的末端很远地映射到一个 功能未知的长非编码RNA(LncRNA),LOC157273。尽管有相当大的物理距离, 研究发现,基因变异与肝脏PPP1R3B RNA的增加有关。次要等位基因(出现在 约9%的欧洲人)与肝脏PPP1R3B mRNA表达增加和肝脏和 血浆脂类。我们在小鼠身上的初步数据强烈表明,PPP1R3B是肝脏特异的致病基因 Ppp1R3B基因敲除小鼠(Ppp1r3bΔHep)肝脏和血浆脂质升高,而 肝脏中Ppp1r3b水平降低肝脏和血脂。我们建议阐明以下机制: 肝脏PPP1R3B影响肝脏脂肪和血浆胆固醇,并确定自然变异体如何 增加PPP1R3B基因的表达。 好了!

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Joseph A. Baur其他文献

Human genetics identify convergent signals in mitochondrial LACTB-mediated lipid metabolism in cardiovascular-kidney-metabolic syndrome
人类遗传学确定了心血管-肾脏-代谢综合征中线粒体 LACTB 介导的脂质代谢中的趋同信号。
  • DOI:
    10.1016/j.cmet.2024.10.007
  • 发表时间:
    2025-01-07
  • 期刊:
  • 影响因子:
    30.900
  • 作者:
    Shen Li;Hongbo Liu;Hailong Hu;Eunji Ha;Praveena Prasad;Brenita C. Jenkins;Ujjalkumar Subhash Das;Sarmistha Mukherjee;Kyosuke Shishikura;Renming Hu;Daniel J. Rader;Liming Pei;Joseph A. Baur;Megan L. Matthews;Garret A. FitzGerald;Melanie R. McReynolds;Katalin Susztak
  • 通讯作者:
    Katalin Susztak
Mitochondrial NAD+ transporter SLC25A51 linked to human aortic disease
线粒体 NAD+转运蛋白 SLC25A51 与人类主动脉疾病相关
  • DOI:
    10.1038/s44161-024-00599-6
  • 发表时间:
    2025-01-22
  • 期刊:
  • 影响因子:
    10.800
  • 作者:
    Gabriel K. Adzika;Ricardo A. Velázquez Aponte;Joseph A. Baur
  • 通讯作者:
    Joseph A. Baur
Swine Models for NAD + Supplementation in Heart Failure
补充 NAD 治疗心力衰竭的猪模型
  • DOI:
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Joseph A. Baur
  • 通讯作者:
    Joseph A. Baur
Resveratrol for primary prevention of atherosclerosis: Clinical trial evidence for improved gene expression in vascular endothelium
  • DOI:
    10.1016/j.ijcard.2012.09.027
  • 发表时间:
    2013-06-05
  • 期刊:
  • 影响因子:
  • 作者:
    Beamon Agarwal;Matthew J. Campen;Meghan M. Channell;Sarah J. Wherry;Behzad Varamini;James G. Davis;Joseph A. Baur;James M. Smoliga
  • 通讯作者:
    James M. Smoliga
Regulation of and challenges in targeting NAD+ metabolism
靶向 NAD+代谢的调控与挑战
  • DOI:
    10.1038/s41580-024-00752-w
  • 发表时间:
    2024-07-18
  • 期刊:
  • 影响因子:
    90.200
  • 作者:
    Marie E. Migaud;Mathias Ziegler;Joseph A. Baur
  • 通讯作者:
    Joseph A. Baur

Joseph A. Baur的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Joseph A. Baur', 18)}}的其他基金

Mechanisms and therapeutic potential of blocking the mitochondrial Mg2+ channel Mrs2 in obesity and NAFLD
阻断线粒体 Mg2 通道 Mrs2 在肥胖和 NAFLD 中的机制和治疗潜力
  • 批准号:
    10679847
  • 财政年份:
    2023
  • 资助金额:
    $ 54.11万
  • 项目类别:
HTS to identify compounds that increase NAD+ levels in neurons and muscle cells
HTS 鉴定可增加神经元和肌肉细胞中 NAD 水平的化合物
  • 批准号:
    10665088
  • 财政年份:
    2022
  • 资助金额:
    $ 54.11万
  • 项目类别:
Understanding the roles of cardiac NAD pools and therapeutic effects of precursor supplements in heart failure
了解心脏 NAD 池的作用以及前体补充剂对心力衰竭的治疗作用
  • 批准号:
    10539858
  • 财政年份:
    2022
  • 资助金额:
    $ 54.11万
  • 项目类别:
Understanding the roles of cardiac NAD pools and therapeutic effects of precursor supplements in heart failure
了解心脏 NAD 池的作用以及前体补充剂对心力衰竭的治疗作用
  • 批准号:
    10680576
  • 财政年份:
    2022
  • 资助金额:
    $ 54.11万
  • 项目类别:
HTS to identify compounds that increase NAD+ levels in neurons and muscle cells
HTS 鉴定可增加神经元和肌肉细胞中 NAD 水平的化合物
  • 批准号:
    10618481
  • 财政年份:
    2022
  • 资助金额:
    $ 54.11万
  • 项目类别:
Mechanisms underlying the genetic association between PPP1R3B and Alzheimer's Disease
PPP1R3B 与阿尔茨海默病之间遗传关联的潜在机制
  • 批准号:
    10288770
  • 财政年份:
    2018
  • 资助金额:
    $ 54.11万
  • 项目类别:
Targeting NAD Metabolism to Improve Glucose Homeostasis in Obesity and Aging
靶向 NAD 代谢以改善肥胖和衰老过程中的血糖稳态
  • 批准号:
    10288703
  • 财政年份:
    2013
  • 资助金额:
    $ 54.11万
  • 项目类别:
Targeting NAD Metabolism to Improve Glucose Homeostasis in Obesity and Aging
靶向 NAD 代谢以改善肥胖和衰老过程中的血糖稳态
  • 批准号:
    8596305
  • 财政年份:
    2013
  • 资助金额:
    $ 54.11万
  • 项目类别:
Targeting NAD Metabolism to Improve Glucose Homeostasis in Obesity and Aging
靶向 NAD 代谢以改善肥胖和衰老过程中的血糖稳态
  • 批准号:
    8731882
  • 财政年份:
    2013
  • 资助金额:
    $ 54.11万
  • 项目类别:
Molecular Mechanisms of Rapamycin's effects on Health and longevity.
雷帕霉素对健康和长寿影响的分子机制。
  • 批准号:
    8852520
  • 财政年份:
    2013
  • 资助金额:
    $ 54.11万
  • 项目类别:

相似海外基金

Deciphering the role of adipose tissue in common metabolic disease via adipose tissue proteomics
通过脂肪组织蛋白质组学解读脂肪组织在常见代谢疾病中的作用
  • 批准号:
    MR/Y013891/1
  • 财政年份:
    2024
  • 资助金额:
    $ 54.11万
  • 项目类别:
    Research Grant
ESTABLISHING THE ROLE OF ADIPOSE TISSUE INFLAMMATION IN THE REGULATION OF MUSCLE MASS IN OLDER PEOPLE
确定脂肪组织炎症在老年人肌肉质量调节中的作用
  • 批准号:
    BB/Y006542/1
  • 财政年份:
    2024
  • 资助金额:
    $ 54.11万
  • 项目类别:
    Research Grant
Canadian Alliance of Healthy Hearts and Minds: Dissecting the Pathways Linking Ectopic Adipose Tissue to Cognitive Dysfunction
加拿大健康心灵联盟:剖析异位脂肪组织与认知功能障碍之间的联系途径
  • 批准号:
    479570
  • 财政年份:
    2023
  • 资助金额:
    $ 54.11万
  • 项目类别:
    Operating Grants
Determinants of Longitudinal Progression of Adipose Tissue Inflammation in Individuals at High-Risk for Type 2 Diabetes: Novel Insights from Metabolomic Profiling
2 型糖尿病高危个体脂肪组织炎症纵向进展的决定因素:代谢组学分析的新见解
  • 批准号:
    488898
  • 财政年份:
    2023
  • 资助金额:
    $ 54.11万
  • 项目类别:
    Operating Grants
Activation of human brown adipose tissue using food ingredients that enhance the bioavailability of nitric oxide
使用增强一氧化氮生物利用度的食品成分激活人体棕色脂肪组织
  • 批准号:
    23H03323
  • 财政年份:
    2023
  • 资助金额:
    $ 54.11万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Development of new lung regeneration therapies by elucidating the lung regeneration mechanism of adipose tissue-derived stem cells
通过阐明脂肪组织干细胞的肺再生机制开发新的肺再生疗法
  • 批准号:
    23K08293
  • 财政年份:
    2023
  • 资助金额:
    $ 54.11万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A study on the role of brown adipose tissue in the development and maintenance of skeletal muscles
棕色脂肪组织在骨骼肌发育和维持中作用的研究
  • 批准号:
    23K19922
  • 财政年份:
    2023
  • 资助金额:
    $ 54.11万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Adipose Tissue T Cell Polarization and Metabolic Health in Persons Living with HIV
HIV 感染者的脂肪组织 T 细胞极化和代谢健康
  • 批准号:
    10619176
  • 财政年份:
    2023
  • 资助金额:
    $ 54.11万
  • 项目类别:
Estrogen Signaling in the Ventromedial Hypothalamus Modulates Adipose Tissue Metabolic Adaptation
下丘脑腹内侧区的雌激素信号调节脂肪组织代谢适应
  • 批准号:
    10604611
  • 财政年份:
    2023
  • 资助金额:
    $ 54.11万
  • 项目类别:
Obesity and Childhood Asthma: The Role of Adipose Tissue
肥胖和儿童哮喘:脂肪组织的作用
  • 批准号:
    10813753
  • 财政年份:
    2023
  • 资助金额:
    $ 54.11万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了